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1. Introduction  
The effect of exogenous and endogenous factors on the thyroid is manifested as 
stimulation or inhibition of the gland's excretory activity and growth regulation of the 
thyroid tissue itself. External factors affecting thyroid enlargement were known as early 
as approximately 2000 years B.C. in ancient China, where marine products were 
administered to inhabitants of the central part of the country. This specific 
supplementation of iodine-rich products prevented goiter development. [1,2] In modern 
times, the first country to introduce iodine prophylaxis was Switzerland, followed by the 
United States. Poland has been implementing a program of common salt iodization since 
1986, albeit with an interruption of less than a score of years. We presently know than 
apart from iodine, there are numerous factors that affect regulation of thyroid secretion 
and growth. Thyroid homeostasis is thus controlled by several different substances acting 
on various levels: directly and indirectly by thyrotropin TSH (thyroid stimulating 
hormone); locally by other growth stimulators, such as the epidermal growth factor 
(EGF), transforming growth factor alpha (TGF-ǂ), insulin growth factors (IGFs), fibroblast 
growth factors (FGFs), hepatocyte growth factor (HGF), platelet-derived growth factor 
(PDGF) and transforming growth factor beta (TGF-ǃ), as well as through programmed cell 
death in the mechanism of apoptosis. Hence, changes in thyroid size and hormone 
demand occur mostly through TSH and complex interactions of local growth factors with 
expression of specific receptors. It has been also observed recently that para- and 
autocrine effects of growth factors are also associated with expression of particular 
oncogenes. Except the embryonal and adolescent periods, the volume of a normal thyroid 
gland does not increase. Each thyroid follicular cell is programmed to undergo five 
mitotic cycles during adult life and the final population of thyrocytes demonstrates 
specific differentiation, manifested by hormone secretion in response to thyrotropin via 
the mechanism of negative feedback. Thus, participation of the thyroid gland in 
hemostasis is regulated via hormonal, neural and immune pathways. The first level of 
thyroid growth and function control occurs via the effect of thyrotropin (TSH). The 
second level of tissue hemostasis is controlled by local factors. The third level consists of 
interactions between thyroid cells and connective tissue stroma, while the fourth level 
includes genetic factors with programmed death cell (apoptosis).   
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2. Regulation of growth and hormonal secretion – Mitogenic pathways  
2.1 Role of TSH 
Mechanism of activation via a receptor (types of receptors) 
Thyrotropin (TSH) is traditionally believed to be the principal stimulator of growth, 
differentiation and maturation of thyroid follicular cells and connective tissue stroma. It is a 
28 kD glycoprotein. Its level is among major parameters describing thyroid function and 
playing a decisive role in the clinical status of a patient. As early as in mid-thirties (1935 
Kippen; Loeb; 1937 Dunhill), observations were made on the effect of TSH on thyroid 
follicular cells. Both a stimulatory and inhibitory effect of thyrotropin on thyroid follicular 
cells was described in cells cultured in vitro; attempts were undertaken at explaining the role 
of suppression therapy in preventing thyroid cancer development. For decades, particular 
research teams obtained contrary results of investigations on the proliferogenic effect on 
growth and differentiation of thyroid follicular cells. The effect on thyroid function and 
hormonal secretion has remained unquestioned [3,4]. In the last decade, numerous reports 
were published that discussed the complex regulation system of thyroid cell growth and 
proliferation, where thyrotropin alone may play an important role, but is not a prerequisite. 
Thus, TSH administration to rats resulted in thyroid enlargement both via cell hypertrophy 
and hyperplasia [5]. TSH-induced thyreocyte proliferation was triggered by human thyroid 
tissue implantation to mice (thymus-deficient nu/nu mice). In another study, thyrotropin 
was not necessary for compensatory thyroid growth following hemithyroidectomies, what 
suggested the effect of other factors that also play a role in the gland's growth [6,7]. 
Recently, attention has been also focused on the role of cAMP in thyroid growth-associated 
processes. Numerous reports on the proliferogenic effect of cAMP on thyroid follicular cells 
point to three pathways of activating growth and proliferation of thyroid cells:  
1. first - activation of the adenyl cyclase-cAMP system, stimulated by TSH;  
2. second - the phosphatidylinositol-Ca ion system,  
3. third - most likely independent of cAMP - protein phosphorylation of tyrosine.  
An increase of cAMP level in the majority of differentiated thyroid tumors (in contrast to 
normal tissue collected from the same patient) was interpreted as a result of an increased 
response to TSH stimulation. In numerous differentiated thyroid cancers, the functional 
TSH-cAMP-thyroid follicular cell growth system was noted; nevertheless, the question on 
intercorrelations of the above factors continue to remain open (Table 1.). Numerous authors 
have also pointed to a double effect of TSH depending on activation of other transmitters. 
Thus, 1) thyroid follicular cell growth is stimulated via activation of phosphatidylinositol 
and protein kinase C, while 2) the function of thyroid follicular cells is regulated by cAMP 
and protein kinase A (Figure 1). The two alternative pathways may explain diversified 
effects of thyrotropin in cancerous thyroid tissue [2]. The turning point in explaining many 
growth-associated phenomena within the thyroid gland was determination of the receptor 
structure on the molecular level and demonstration of intracellular interactions via 
activation of other transmitters. The thyrotropin receptor itself belongs to the family of G 
protein-coupled receptors (similarly as FSH, LH, estrogens, hCG or other steroid receptors). 
The predominant property of all the above receptors is the presence of a transmembrane 
domain that crosses the lipid layer (Figure 2.). The N-terminal region of the receptors is the 
so-called ectodomain situated on cell surface. The C-terminal region, situated within the cell, 
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is much shorter. The TSH receptor, in contrast to other receptors from this family, is 
modified post-translationally. Approximately 75% of the monomeric, membrane receptor is 
proteolized. In consequence of proteolysis, the so-called peptide C is released, while the 
generated subunits A and B are linked by disulfide bridges. Both forms of the receptor - 
monomeric and dimeric - actively bind TSH. In the cell membrane of thyrocytes, the TSH 
receptor is found in two forms: active, which binds Gs protein, and inactive, which is 
prevalent. Both TSH and stimulating autoantibodies bind to the active form of the receptor 
and stabilize it. In turn, inhibiting antibodies stabilize the inactive ("closed") form of the 
receptor and thus, the genuine receptor agonist seems to be the active ("open") form of the 
receptor rather than the thyrotropin (TSH) molecule itself [8,9,10,11]. 
3. Vascular endothelial growth factor (VEGF), epidermal growth factors 
(EGFs) and transforming growth factor alpha (TGF-α) 
Neoangiogenesis is a process consisting of numerous paracrine and endocrine interactions 
between cancer cells and vascular endothelial cells, connective tissue stromal cells and some 
morphotic blood elements, such as macrophages or mastocytes. The result of such 
interactions is a change in the microenvironment of a tumor that allows for its further 
uncontrollable growth and progression. A prerequisite for initiation of angiogenic 
phenomena is disturbance of balance between the system of pro- and anti-angiogenic 
factors. Not each of the proangiogenic factors that have been described to date (VEGF; 
bFGF; aFGF; PDGF; TGF-ǂ; TGF-ǃ; EGF; IGF-1) meets all the three characteristic criteria: 
exerting a specific effect on endothelium, possessing a system of specific cell receptors and 
manifesting fluctuations that inhibit or induce angiogenesis. Many of such factors, acting in 
conjunction with mediators secreted by other cells (e.g. macrophages - TNF), induce and 
promote development of cancer. In keeping with the presently accepted assumptions, 
angiogenesis is initiated via hypoxia of cancer cells that are situated at the highest distance 
from the lumen of a blood vessel, as well as via a defect of the genetic apparatus, the 
consequence of which is formation of the so-called angiogenic phenotype. This term denotes 
a state of permanent, constitutive activation of growth factors-encoding genes. An 
additional loss of function of suppressor genes (e.g. the p53 gene) favors the process of 
neoangiogenesis. One of the relatively well-understood epithelial growth factors is VEGF. 
This specific protein, defined and named in late eighties, is assumed to play a key role in 
vascularization of solid tumors, including thyroid tumors. At present, the VEGF group is 
believed to include six proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF 
(Placenta Growth Factor). They act through binding to receptors: VEGFR1, VEGFR2 – on 
vascular endothelial cells, and VGFR3 – on lymphatic endothelium cells (Figure 3). The 
necessary cofactors for the VEGF receptor are neuropilins 1 and 2 (Nrp-1,2), which are 
indispensable for proper activation of the receptor by a ligand. Synthesis of the vascular 
growth factor is induced by numerous other substances, such as nitrogen oxide, insulin, 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), tumor necrotic factor (TNF-ǂ), transforming growth factor (TGF-ǃ), IL-1,2. In 
keeping with the theory of Folkman, which states that tumor growth is limited by its 
vascularization, attempts have been made to demonstrated higher VEGF expression in 
cancer tissues as compared to normal cell populations. Similarly as in the case of cancer of 
the stomach, colon, uterus, breast and ovary, also in thyroid tumors a key role in 
neoangiogenesis is played by VEGF. As it has been already mentioned, not only thyroid 
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epithelial cells, but also stromal cells are capable of producing and secreting VEGF. The 
above described results have allowed for formulating a hypothesis that VEGF participates in 
initiation of neoangiogenesis, yet further tumor development and progression most likely 
depend on the effect of other chemokines secreted both by tumor cells, its stroma and 
macrophages migrating to the neoplastic lesion [12.13,14]. In turn, epidermal growth factor 
EGF is one of the most potent stimulators of thyroid growth and its multiple effect is 
determined by its binding to specific EGF receptors. In vitro, it is a factor that stimulates 
proliferation of thyroid follicular cells. A factor that increases EGF binding to receptors is 
thyrotropin (TSH), which – stimulating the increase of the number of EGF receptors - 
enhances its effect. Yet, in contrast to the above-mentioned TSH, to reveal its mitogenic 
effect, EGF does not require the presence of other chemokines. In subsequent studies, 
investigators attempted to determine the effect of positive EGF receptors expression in 
thyroid cancer tissue on the clinical course of the disease. A comparison was made between 
the presence of EGF receptors in various types of thyroid cancer, finding their highest 
expression in anaplastic and medullary carcinoma of the thyroid. Also adenomas 
demonstrated considerable expression of EGF receptors, but only in some limited areas 
within the tumor. EGF-R was also noted to bind not only to EGF -ǂ l, but also to the 
transforming growth factor alpha (TGF-ǂ). The autocrine mechanism of activating EGF 
receptors both by the epidermal growth factor molecule and by TGFǂ was seen in thyroid 
cancers (papillary carcinoma and its nodal metastases) [15]. 
4. Insulin growth factors and their receptors (IGFs) 
Growth hormone (GH) affects growth processes in tissues and organs through specific 
substances called the insulin growth factors (IGF-I; IGF-II). IGF-I, termed somatomedin C, 
and IGF-II affect growth regulation of thyroid endothelial cells. In turn, thyroid follicular 
cells show high expression of specialized IGF-I and IGF-II receptors. The IGF-I receptor, as a 
member of the family of receptors that act via tyrosine kinase, is a mediator of the effect of 
IGF-I on stimulation and growth of thyroid follicular cells. IGF-I has been proven to strongly 
stimulate growth of the FRTL-5 line cells and to synergistically enhance the mitogenic effect 
of thyrotropin (TSH). In turn, the IGF-II receptor plays no significant role in thyroid growth 
stimulation. Autocrine secretion of IGF-I, IGF-II and expression of the IGF-I-Rs receptor 
were demonstrated in primary cultures of thyroid follicular cells, as well as in adenomas 
and thyroid papillary carcinoma cell lines [16,17,18].  
5. Fibroblast growth factor (FGFs), hepatocyte growth factor (HGF), platelet-
derived growth factor (PDGF) 
To date, nine subtypes of the fibroblast growth factor belonging to a single family (the "FGF 
family") have been determined. The FGF factor itself is known as a stimulator of 
proliferation, differentiation and functioning of various diverse cells of human body. FGF 
also plays a significant role in neoangiogenesis. The cell response to FGF effect is mediated 
by its four receptors (FGF-R 1-4) that belong to the family of tyrosine kinases. Thyroid 
endothelial cells show expression of FGF-R receptors, while the basement membrane of 
thyroid follicular cells is capable of producing the factor itself. Based on numerous 
observations in vitro and in vivo in rat thyroid follicular cells, an autocrine, stimulatory 
effect of FGF-2 ("basic FGF") on thyroid growth processes has been demonstrated. In turn, a 
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paracrine effect has been manifested in neovascularization seen in nodular goiter. Similarly 
as EGF, FGF has an inhibitory effect on thyroid function. The effect of FGF consists in 
inhibition of cAMP activation and weakening of TSH activity. FGF-1 administration to rats 
leads to development of colloid goiter, most likely through inhibition of TSH-dependent 
colloid transport from the lumen of thyroid follicles (Figure 4.). 
The hepatocyte growth factor (HGF) is also a potent myogen for numerous diversified cell 
types in human body, especially these of epithelial origin. It operates through its receptor 
that is encoded by the c-met proto-oncogene and belongs to the family of tyrosine kinase 
receptors. HGF-R expression has been noted both in normal and cancer tissue, with the 
factor being present in papillary and follicular carcinoma, but absent in anaplastic 
carcinoma tissue. Some importance in neoplastic proliferation is also ascribed to the platelet-
derived growth factor PDGF), the presence of which has been noted in the papillary 
carcinoma cell line.  
6. Interactions between stimulatory growth factors and their inhibitors  
A group of factors that inhibit thyroid growth is the family of the thyroid growth inhibiting 
factor – ǃ (TGF- ǃ). Through their receptors TGF- ǃ-R I to TGF- ǃ-R III, the factors TGF- ǃ1 to 
TGF- ǃ3 affect inhibition of thyroid follicular cell growth in vitro; their role has also been 
implicated in development of benign lesions. A drop in TGF production has been observed 
in thyroid follicular cells of patients with non-toxic goiter.  
Stimulation of thyroid tissue growth occurs through an increased frequency of signals 
reaching the gland from the surrounding structures, resulting in sensitization of follicular 
cells to normal external stimuli. Such stimuli may be the afore-mentioned growth factors 
or antibodies or else dietary iodine deficit. A notion of the so-called "grey zone" has 
become popular in thyreology, to denote a population of cells with a high internal growth 
potential, which, in consequence of single or multiple genetic damage, change their 
growth potential (in hyperplastic tumors) towards cancer, yet without obvious neoplastic 
transformation. The effect on cell cycle, manifested as for example the shortened G0 phase 
or limitation of apoptosis may lead to an increase in the number of cell divisions prior to 
programmed cell death.  
Within the past decade, development of modern research methods, molecular biology and 
genetics has allowed for gradual understanding of molecular foundations of thyroid 
cancers. It is presently known that activation of certain oncogenes and inactivation of 
suppressor genes may lead to tumor development. Of 35 proto-oncogenes determined in 
neoplastic transformation of thyroid follicular cells, the following have their effect proven: 
1. c-erb encodes the EGF (endothelial growth factor) receptor; 
2. flg, bek encodes the FGF receptor type 1 and 2 (fibroblast growth factor); 
3. c-met encodes the HGF (hepatocyte growth factor) receptor; 
4. c-sis encodes the PDGF (platelet-derived growth factor) receptor; 
5. Ras is characteristic of follicular carcinoma, adenoma, anaplastic carcinoma; 
6. PTC/ret, TPC – characteristic of papillary carcinoma; 
7. Trk encodes NGF (nerve growth factor) characteristic of papillary carcinoma and 
detected in nodular goiter.  
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As it follows from the presented data, they play a key role in encoding growth factors 
and/or their receptors production  
Summing up, it should be stressed that the theories presented in the chapter constitute only 
a very narrow fragment of the bulk of knowledge on the subject. An extensive presentation 
of the topic is possible only in a monograph, yet the above provided examples help in 
understanding the foundations of contemporary knowledge on the effect of external factors 
on cancer development.  
 
Fig. 1. Mitogenic pathways in regulation of thyroid function and growth. The scheme 
present the main pathways that participate in regulation of thyroid function and growth.  
1. The AC/cAMP/PKA pathway: The main factor that stimulates the pathway in 
thyrocytes is thyrotropic hormone (TSH), which interacts with the TSH receptor (TSH-
R). Stimulation of the TSH-R receptor leads to activations that bind guanosine 
triphosphate (GTP) of regulatory proteins; Ga protein in the plasma membrane 
activates adenyl cyclase (AC) that synthesizes cyclic adenosine monophosphate 
(cAMP), which activates protein kinase A (PKA), and phospholipase C (PLC)-associated 
Gp protein, which stimulates phosphatidylinositol (PI) metabolism.  
2. The PI-PKC-Ca2+ pathway: In addition to TSH-R, the cascade of signal transmission is 
activated through numerous diversified receptors (marked as Rn in the scheme). 
Stimulation of TSH and other receptors leads to an increased PLC activity; in 
consequence, 1,4,5,-inositol triphosphate (IP3) and diacylglycerol (DAG) are formed with 
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a resultant increase of intracellular level of calcium (Ca2+) and PKC activity. Both PKA 
and PKC are serine-threonine kinases and they phosphorylate several different proteins.  
3. The receptor tyrosine kinase pathway (RTK): Binding of a ligand to RTK leads to 
phosphorylation of tyrosine residues in the receptor molecule. The stimulated 
phosphorylated receptors connect to numerous different signaling pathways (the scheme 
does not show all the pathways) through direct binding of signaling proteins that contain 
a homology domain with Src proteins (SH2). Nevertheless, the main mitogenic pathway 
of numerous receptors tyrosine kinase (RTK) includes activation of a chain of events on 
the ras pathway (see the scheme). In brief, phosphorylated RTK interacts with Grb2 
adaptor protein. Grb2 binds to a protein called Sos ("son of sevenless"), resulting in 
activation of the ras pathway. The activated form of ras GTP protein triggers increased 
activity of raf protein, with a resultant sequential activation of MAPK cascade proteins 
(mitogen-activated kinases), what ultimately leads to an increased transcriptional activity 
(MAPKK kinase, MAPK). The scheme also shows a negative effect of organic forms of 
iodine (I-X) on various pathways. ATP = adenosine triphosphate.  
 
NH 2 A/B 
C 
DNA
D 
E 
HORMONES 
F COOH 
    
Thyroid hormones Vitamin D Estrogens; 
Androgens; Progesterone; Glucocorticoids; 
Mineralocorticoids;  
  
Fig. 2. The family of steroid/thyroid receptors. The marked receptors have similar structure. 
The C domain consists of DBD domains.  
VEGF-A VEGF-B VEGF-C VEGF-D Ang-1 Ang-2
VEGFR-1 VEGFR-2 VEGFR-3 Tie - 2
Migration of 
smooth muscle 
cells
Development of 
small vessels
angiogenesis
arteriogenesis
Development of 
small lymph vessels
Tie-2
arteriogenesis
(Ang-1)
angiogenesis
(Ang-2 + VEGF)
Angiogenesis inhibitor
(Ang-2)  
Fig. 3. Vascular growth factors and the effects of their acting through receptors.  
www.intechopen.com
 
Thyroid and Parathyroid Diseases – New Insights into Some Old and Some New Issues 
 
84
 
Fig. 4. Autocrine and paracrine regulation of growth and inhibition of thyrocytes via growth 
factors and their receptors. The factors may be also secreted by the surrounding stromal 
tissue, thus giving rise to proliferation of endothelial cells and fibroblasts. IGF-insulin 
growth factor; TGF – transforming growth factor; EGF – epidermal growth factor; FGF – 
fibroblast growth factor; PDGF – platelet-derived growth factor.  
Activation pathway
(other transmitter)
Factors Receptor Effect 
“Related” 
proto-oncogene 
AC-cAMP-PKA 
TSH 
TSH-R 
Stimulatory 
and 
inhibitory
 
Iodides (inhibition 
of cAMP
Stimulatory  
Epinephrine
(inhibition of 
cAMP) 
Stimulatory  
Receptor tyrosine 
kinases  
EGF EGF-R Stimulatory c-erb B (EGF-R) 
TGF-a EGF-R Stimulatory
FGFs FGF-Rs (1-4) Stimulatory
fIg, bek (FGF-R-
I, FGF-R-2) 
Insulin (ffi) IGF-I-R 
Stimulatory 
(via IGF-I-R)
 
IGF-I IGF-I-R Stimulatory
IGF -n (IGF-n-R) IGF-I-R
Stimulatory 
(via IGF-I-R)
 
HGF HGF-R Stimulatory c-met (HGF-R) 
PDGFs (AA, AB, 
BB)
PDGF-Rs (a, ) Stimulatory c-sis (PDGF-BB) 
Phosphatidylinositol 
cascade  
TSH TSH-R Stimulatory
Esters PKC Stimulatory
TGF -ǃ1 TGF--Rs (1-3) Inhibitory
 Iodides  Inhibitory  
Table 1. Major factors with stimulatory and inhibitory effect on growth of thyroid follicular 
cells.  
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